Gain Therapeutics, Inc.GANXNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank29
Studio
Year-over-Year Change

Cash generated from core business operations

Latest
$-17.30M
↓ 57% vs avg
Percentile
P29
Within normal range
Streak
1 yr
Consecutive growthContracting
Average
$-10.99M
Historical baseline
PeriodValueYoY Change
TTM$-17.30M+8.3%
2024$-18.87M-0.0%
2023$-18.87M-28.4%
2022$-14.69M-18.8%
2021$-12.37M-281.6%
2020$-3.24M-73.4%
2019$-1.87M-151.0%
2018$-744514.00-